Research progress of therapeutic drug monitoring of tyrosine kinase inhibitors commonly used in non-small cell lung cancer
ZHOU Guo-jin
WU Jing-jing
XU Jing
CHEN Jie
Abstract：Tyrosine kinase inhibitors have dramatically improved the prognosis of patients with advanced non-small cell lung cancer.In clinical settings,however,it is observed that the treatment response and pharmacokinetics show the characteristics of substantial variability among individuals.In such case,therapeutic drug monitoring is applied to guiding personalized medicine by researchers in succession and has remarkable results.Yet some of the tyrosine kinase inhibitors are still lack of corresponding target concentration or therapeutic window,and the exposure-response relationship remains unclear.Therefore,the aim of this review is to elucidate the current research progress of therapeutic drug monitoring for the first-line oral targeted drugs commonly used in advanced non-small cell lung cancer,such as gefitinib,erlotinib,icotinib,afatinib,dacomitinib,osimertinib,alectinib,crizotinib and ceritinib,in order to provide reference for clinical practice.
Keywords：lung cancertyrosine kinase inhibitortherapeutic drug monitoringpharmacokineticexposure-response relationship
Publication Date：2024-01-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 55-61 )